Preclinical pharmacology and toxicology studies
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261200433006C
- Awardee
-
University Of Illinois UEI W8XEAJDKMXH3 Part of University Of Illinois
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,371,919
Award facts
- Contract value 26% obligated
- $24,207,156.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 8 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Chicago, IL 60612, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$144,582 | |
| Other Administrative Action | -$78,573 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $323,794 | |
| Supplemental Agreement for work within scope | $326,202 | |
| Funding Only Action | $1,278,125 | |
| Funding Only Action | $60,660 | |
| Funding Only Action | $1,250,000 | |
| Funding Only Action | $1,100,000 | |
| Funding Only Action | $1,136,246 | |
| Original award | $1,120,048 |
Show all 12
About this award
This is a definitive contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to the University of Illinois for preclinical pharmacology and toxicology studies. The contract, valued at $24,207,156.38, does not have a set-aside designation.
The University of Illinois, a major public research institution, is conducting research and development work to support the PREVENT Cancer Preclinical Drug Development Program, a structured approach to developing cancer drugs and vaccines from discovery through clinical trials. This contract is part of a larger $149,995,000 Indefinite Delivery Indefinite Quantity (IDIQ) contract held by the university to evaluate the efficacy and biomarkers of cancer prevention regimens, support preclinical product development and manufacturing for candidate cancer prevention vaccines, and assess the pharmacological and toxicological effects of preventative agents. Through this contract, the University of Illinois is providing the National Cancer Institute with critical preclinical research to advance new cancer prevention therapies.
Quick answers
Who was awarded contract HHSN261200433006C?
HHSN261200433006C was awarded to University Of Illinois by National Cancer Institute (National Institutes of Health) on June 30, 2004.
How much is contract HHSN261200433006C worth?
The government has obligated $6,371,919 on HHSN261200433006C. Its current value, with exercised options, is $24,207,156.
Was contract HHSN261200433006C competed?
The extent of competition for HHSN261200433006C was full and open competition. The government received 8 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award